Lipid-based drug delivery systems in the treatment of wet age-related macular degeneration

2016 ◽  
Vol 6 (6) ◽  
pp. 781-792 ◽  
Author(s):  
Joanne D. Du ◽  
Wye-Khay Fong ◽  
Suzanne Caliph ◽  
Ben J. Boyd
Keyword(s):  
Drug Delivery ◽  
Macular Degeneration ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Age Related Macular Degeneration ◽  
Age Related

Intravitreal anti-VEGF drug delivery systems for age-related macular degeneration

2020 ◽  
Vol 573 ◽  
pp. 118767 ◽  
Author(s):  
Andrea Luaces-Rodríguez ◽  
Cristina Mondelo-García ◽  
Irene Zarra-Ferro ◽  
Miguel González-Barcia ◽  
Pablo Aguiar ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Macular Degeneration ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Age Related Macular Degeneration ◽  
Anti Vegf ◽  
Age Related

Advanced Hydrogels Based Drug Delivery Systems for Ophthalmic Delivery

2020 ◽  
Vol 13 (4) ◽  
pp. 291-300 ◽  
Author(s):  
Srividya Gorantla ◽  
Tejashree Waghule ◽  
Vamshi Krishna Rapalli ◽  
Prem Prakash Singh ◽  
Sunil Kumar Dubey ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Age Related Macular Degeneration ◽  
Stimuli Responsive ◽  
Duration Of Action ◽  
Age Related ◽  
Aqueous Gels ◽  
Ophthalmic Delivery ◽  
3D Printed

Hydrogels are aqueous gels composed of cross-linked networks of hydrophilic polymers. Stimuli-responsive based hydrogels have gained focus over the past 20 years for treating ophthalmic diseases. Different stimuli-responsive mechanisms are involved in forming polymer hydrogel networks, including change in temperature, pH, ions, and others including light, thrombin, pressure, antigen, and glucose-responsive. Incorporation of nanocarriers with these smart stimuli-responsive drug delivery systems that can extend the duration of action by increasing ocular bioavailability and reducing the dosing frequency. This review will focus on the hydrogel drug delivery systems highlighting the gelling mechanisms and emerging stimuli-responsive hydrogels from preformed gels, nanogels, and the role of advanced 3D printed hydrogels in vision-threatening diseases like age-related macular degeneration and retinitis pigmentosa. It also provides insight into the limitations of hydrogels along with the safety and biocompatibility of the hydrogel drug delivery systems.

scholarly journals Novel delivery systems of active substances for intraocular administration

2021 ◽  
Vol 87 (87(03)) ◽  
pp. 331-338
Author(s):  
Rocío Herrero Vanrell
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
The Elderly ◽  
Delivery Systems ◽  
Posterior Segment ◽  
Age Related Macular Degeneration ◽  
Multifactorial Diseases ◽  
Age Related ◽  
Intraocular Drug Delivery ◽  
Active Substances

Neurodegenerative pathologies affecting the posterior segment of the eye such as diabetic retinopathy, age related macular degeneration and glaucoma are among the main causes of blindness in the world. They have in common that are cronic, multifactorial and in some cases related with the elderly. The treatment of these pathologies require to maintain therapeutic concentrations in the posterior segment thanks to the use of successive intraocular injections which are associated to secondary effects being poor tolerated by patients. Intraocular drug delivery systems emerged as an alternative to frequent injections as they are able to deliver the therapeutic agent in a controlled fashion into the eye after a single administration. Depending on the biomaterial these delivery systems are biodegradable or non biodegradable. Attending to their sizes, drug delivery systems are classified in implants (>1mm), microsystems (1-1000μm) y nanosystems (1-1000nm). Biodegradable microspheres emerge as therapeutic tools of great interest for the treatment of neurodegenerative pathologies as they can encapsulate active substances of distinct nature and provide release profiles tailoring with clinical needs. Furthermore, it is possible to administer different amounts of microspheres which correspond to the most adequated doses of the medicine in a personalized therapy. The simultaneous encapsulation of several active substances in the microspheres are of great interest in the treatment of multifactorial diseases covering different therapeutic targets.

scholarly journals Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part I: Biomaterials-Based Drug Delivery Devices

2020 ◽  
Vol 8 ◽  
Author(s):  
Nahla Jemni-Damer ◽  
Atocha Guedan-Duran ◽  
María Fuentes-Andion ◽  
Nora Serrano-Bengoechea ◽  
Nuria Alfageme-Lopez ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Macular Degeneration ◽  
Therapeutic Strategies ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Drug Delivery Devices

An Implantable Device Design Concept for Ocular Drug Delivery

2012 ◽  
Author(s):  
Jae-Hwan Lee ◽  
Ramana M. Pidaparti
Keyword(s):  
Drug Delivery ◽  
Macular Degeneration ◽  
Ocular Drug Delivery ◽  
Eye Diseases ◽  
Age Related Macular Degeneration ◽  
Intravitreal Injections ◽  
Delivery Device ◽  
Drug Delivery Device ◽  
Age Related ◽  
Intraocular Hemorrhage

New drugs for curing eye diseases have been developing for a decade and are very unique for each eye diseases such as glaucoma, cataracts, and age-related macular degeneration (AMD). It is estimated that 1.6 million adults in the US over the age of 50 and above suffer from age-related macular degeneration and about 200,000 cases are diagnosed annually. Worldwide, about 500,000 cases are diagnosed annually [1]. Drugs currently utilized for AMD are delivered via repeated intravitreal injections of the drug into the eye. Risks of repeated intravitreal injections can include intraocular infections (endophthalmitis), intraocular hemorrhage, and retinal detachment. Also, reducing the frequency of dosing will clearly benefit the patient by reducing the need for risky intravitreal injections and improving the pharmacokinetics of the drug in the eye. The eye disease of posterior segment (Dry and Wet) has limits to deliver the drug to retina region using typical eye drop. The drug injection using a needle with syringe can deliver but it barely provide right amount of doses, or over doses that may cause more severe problem such as swelling, fatigue, and damaging photoreceptor molecules. Furthermore, most drugs run away in a month so that repeated injection is necessary. Developing an implantable drug delivery device will help reduce the costs and risks associated with frequent injections and facilitate delivering the drug in a controlled manner and in the required amounts, and improve therapeutic efficacy and safety of drugs. This study focuses on the design, simulation and development of the implantable ocular drug delivery device.

scholarly journals Nanotechnology for Age-Related Macular Degeneration

Pharmaceutics ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 2035
Author(s):  
Bo Yang ◽  
Ge Li ◽  
Jiaxin Liu ◽  
Xiangyu Li ◽  
Shixin Zhang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Gene Therapy ◽  
Macular Degeneration ◽  
Vision Loss ◽  
Cumulative Risk ◽  
Age Related Macular Degeneration ◽  
Delivery Methods ◽  
Age Related ◽  
Therapy Strategies ◽  
Endothelial Growth Factor

Age-related macular degeneration (AMD) is a degenerative eye disease that is the leading cause of irreversible vision loss in people 50 years and older. Today, the most common treatment for AMD involves repeated intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs. However, the existing expensive therapies not only cannot cure this disease, they also produce a variety of side effects. For example, the number of injections increases the cumulative risk of endophthalmitis and other complications. Today, a single intravitreal injection of gene therapy products can greatly reduce the burden of treatment and improve visual effects. In addition, the latest innovations in nanotherapy provide the best drug delivery alternative for the treatment of AMD. In this review, we discuss the development of nano-drug delivery systems and gene therapy strategies for AMD in recent years. In addition, we discuss some novel targeting strategies and the potential application of these delivery methods in the treatment of AMD. Finally, we also propose that the combination of CRISPR/Cas9 technology with a new non-viral delivery system may be promising as a therapeutic strategy for the treatment of AMD.

Nanotechnology for Omics-Based Ocular Drug Delivery

Oncology ◽  
2017 ◽  
pp. 366-381
Author(s):  
Anjali Hirani ◽  
Aditya Grover ◽  
Yong Woo Lee ◽  
Yashwant Pathak ◽  
Vijaykumar Sutariya
Keyword(s):  
Drug Delivery ◽  
Molecular Markers ◽  
Drug Delivery Systems ◽  
Diagnostic Techniques ◽  
Age Related Macular Degeneration ◽  
Ocular Diseases ◽  
Age Related ◽  
Conventional Drug ◽  
Genomics And Proteomics ◽  
Translational Level

Millions of people suffer from ocular diseases that impair vision and can lead to blindness. Advances in genomics and proteomics have revealed a number of different molecular markers specific for different ocular diseases, thereby optimizing the processes of drug development and discovery. Nanotechnology can increase the throughput of data obtained in omics-based studies and allows for more sensitive diagnostic techniques as more efficient drug delivery systems. Biocompatible and biodegradable nanomaterials developed through omics-based research are able to target reported molecular markers for different ocular diseases and offer novel alternatives to conventional drug therapy. In this chapter, the authors review the pathophysiology, current genomic and proteomic information, and current nanomaterial-based therapies of four ocular diseases: glaucoma, uveal melanoma, age-related macular degeneration, and diabetic retinopathy. Omics-based research can be used to elucidate specific genes and proteins and develop novel nanomedicine formulations to prevent, halt, or cure ocular diseases at the transcriptional or translational level.

Sign in / Sign up

Export Citation Format

Share Document